Business Context and Reporting Period
Company: Dr. Reddy's Laboratories Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Fiscal Year ended March 31, 2007 (FY07) and Fourth Quarter (Q4) ended March 31, 2007.
Filing Date: June 26, 2007 (Results announced May 18, 2007).
The filing presents unaudited financial results for FY07, highlighting a transformational year driven by significant acquisitions (including Betapharm in Germany and a CPS business in Mexico) and the launch of key authorized generic products in the US.
Key Financial Metrics
| Metric | FY07 (USD Millions) | FY07 (INR Millions) | FY06 (USD Millions) | FY06 (INR Millions) |
|---|---|---|---|---|
| Total Revenue | 1,510 | 65,095 | 563 | 24,267 |
| Net Income | 216 | 9,327 | 38 | 1,630 |
| Diluted EPS | - | 58.56 | - | 10.62 |
| Cash Flow from Operations | 274 | 11,800 | - | - |
| Gross Margin | 47% | - | 49% | - |
| Net Margin | 14% | - | 7% | - |
| Total Borrowings | 574 | 24,754 | 719 | 30,995 |
| Cash & Equivalents | 431 | 18,588 | 227 | 9,788 |
Note: USD figures are based on a convenience translation rate of 1 USD = 43.10 INR.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 168% year-over-year (YoY), crossing the $1.5 billion mark. International revenue grew 250% to $1.297 billion, now accounting for 86% of total revenue (up from 66% in FY06).
- Profitability: Net income surged 472% to $216 million. Q4 FY07 turned a net loss of $5 million in Q4 FY06 into a net income of $75 million.
- Segment Performance:
- Generics: Revenue jumped 719% to $771 million, driven by US authorized generics (simvastatin, finasteride) and the Betapharm acquisition in Europe.
- APIs: Revenue grew 44% to $276 million, led by sertraline, rabeprazole, and ramipril.
- Custom Pharmaceutical Services (CPS): Revenue increased 397% to $153 million, largely due to the Mexico acquisition.
- One-Time Items: The company recorded a write-down of intangible assets of $41 million (Rs 1,770 million), primarily related to Betapharm product intangibles due to healthcare reforms and price erosion in Germany.
Guidance, Outlook, and Risks
- Dividend: The Board recommended a final dividend of Rs 3.75 per share.
- Product Pipeline: The company filed 23 US DMFs and 33 ANDA filings during the year. Key launches include Fexofenadine and Ondansetron (180-day exclusivity), which contributed significantly to Q4 margins.
- Market Position: Improved market ranking in Russia (15th in retail segment) and India (fastest growing among Top 10 companies).
- Risks & Contingencies:
- Regulatory/Price Erosion: Significant price erosion in the German market (Betapharm) due to healthcare reforms led to intangible write-downs.
- Forward-Looking Statements: Risks include changes in global economic conditions, market acceptance of products, and technological changes.
- Interest Expense: Net interest expense increased to $1,054 million in FY07 (from income in FY06) due to the full-year effect of long-term debt obtained in March 2006.
Investor Verification Checklist
- Acquisition Impact: Verify the sustainability of revenue growth excluding the one-time contributions from Betapharm (Germany) and the Mexico CPS acquisition.
- Authorized Generics Margins: Assess the long-term margin profile of authorized generic products (simvastatin, finasteride) which currently have lower margins than the company average.
- Intangible Asset Valuation: Review the rationale and future impact of the $41 million write-down on Betapharm intangibles.
- Debt Servicing: Monitor the impact of increased interest expenses on future cash flows given the rise in total borrowings.
- Regulatory Approvals: Track the status of the 69 pending ANDAs with the USFDA to gauge future revenue streams.